Podcasts about medical affairs

The future of aesthetics isn't just about smoothing lines—it's about stimulating regeneration and optimizing long-term skin health. In this episode of The Technology of Beauty, Dr. Grant Stevens interviews Bill Andriopoulos, VP Medical Affairs at Galderma, to explore how science is reshaping aesthetic medicine.Bill Andriopoulos walks us through Galderma's evolving approach to innovation, including its focus on real-world outcomes, diverse patient populations, and cutting-edge technologies such as biostimulatory HA fillers. With a career that spans both scientific research and medical strategy, he brings a unique lens to how the company designs, tests, and refines its global portfolio.You'll hear how Galderma is approaching regenerative aesthetics, why combination therapies are key to personalized outcomes, and what it takes to translate breakthrough science into tools that providers can trust. From molecule to market, this episode covers it all.If you're curious about what's next in aesthetics—and who's making it happen—this conversation is not to be missed.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | thetechnologyofbeauty https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level.Subscribe here: https://www.influxmarketing.com/next-level-practices/» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

On this episode of the IPhO Podcast, we're spotlighting the inspiring journey of Dalila Masic, PharmD, Regional Medical Director - T1D Immunology at Sanofi. In this conversation with host Alena Abraham, PharmD, Dalila shares her path from completing PGY1 and PGY2 residencies in critical care at Loyola Medicine to beginning her industry career as a Medical Science Liaison in cardiovascular medicine and how she progressed into her current role, where she leads a team of 10 MSLs focused on autoimmune type 1 diabetes. She reflects on her transition from clinical practice to industry, the transferable skills that supported her pivot, and her leadership philosophy when coaching her team: anchored in clarity, curiosity, and confidence. Dalila also debunks myths about Medical Affairs, offers actionable advice for breaking into pharma without a fellowship, and shares strategies for students and early-career professionals to build credibility via science communication, curiosity, and networking. Whether you're exploring Medical Affairs for the first time or seeking leadership insights to guide your path, this episode delivers perspective and inspiration you won't want to miss!

In today's rapidly evolving healthcare landscape, leadership in the pharmaceutical industry is entering a new era—one defined by innovation, agility, and purpose-driven impact. This transformation is especially visible in Medical Affairs, where the role is shifting from traditional scientific support to becoming a strategic driver of patient-centered value, cross-functional collaboration, and real-world evidence generation. In this special series, Bagrat Lalayan sits down with prominent industry leaders to explore how modern leaders are navigating global challenges, embracing digital transformation, and redefining success in a more complex and regulated environment. Together, they'll discuss the skills, mindsets, and strategies required to lead with vision, foster trust, and accelerate innovation—while keeping patient outcomes at the heart of every decision.

Today on From Lab To Launch, we're excited to welcome Dr. Terrance Govender, the VP of Medical Affairs at ClinIntell.ClinIntell, based in Tampa, Florida, supports healthcare executives and leaders in accurately capturing the true severity of their inpatient population using population-based predictive analytics. The results for their customers? More accurate, trustworthy performance data and clinical condition reporting, that can be easily shared and used to drive continuous improvement activities. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In the 2025 Payer Oncology Trend Report, we analyze how health plans and PBMs are navigating the shifting landscape of branded cancer drug management. To deepen our findings, we spoke with industry experts Michael Kolodziej, MD, and Ira Klein, Vice President, Medical Affairs & Payer Relations at Tempus, who shared their perspectives on the data, key trends, and what these insights mean for manufacturers moving forward.

On this episode of Alloutcoach, host Tim Mikhelashvili, CEO, Amedea Pharma convenes a panel you rarely hear in one room: a policy-minded biohacker and investor (John Hemming, CEO of Cirrostratus, Biohacking Team Leader), a strategy and operations leader who reshapes patient journeys (Bart Zoni, Senior Vice President, Marketing, Woven Health Collective), and an early-stage investor focused on medical technologies (Chris Piedmonte, Managing Director, Neoterra Capital) as well as a senior pharma thought leader in Medical Affairs and Health Economics, Janelle Hardisty. Their catalyst? Fresh takeaways from the 2025 Financial Times US Pharma summit — and an honest look at what's truly accelerating innovation, what's stalling it, and where capital and talent should go next.00:00:00 Cold Open - Episode Highlights: AI accuracy and access00:03:43 Host Intro and Why This Episode00:04:41 Guest Intros00:08:06 State of Innovation - Tailwinds and Headwinds00:12:41 What's Really Accelerating Innovation?00:19:27 Drug Discovery - Reducing the 90% Failure Rate00:22:01 Clinical Trials - Modernize or Stall00:25:11 Access, PBMs, and Direct-to-Patient00:27:03 Longevity and Prevention - Can We Measure It?00:36:52 Data Culture Maturity and Pilot Fatigue00:45:52 Training the Future Workforce00:51:09 Investing - Where Should Capital Flow?00:57:08 Regulatory Reality and Time-to-Access00:59:27 Closing and Invite to Medical Innovation Olympics

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

This episode features a powerful discussion with Dr. Padma Mahant, Director of Medical Affairs, CND Life Sciences, and Dr. Indu Subramanian, a Neurologist with UCLA, who are leading the charge to correct the biases in Parkinson's disease care. They expose a critical gap where women's unique, non-motor symptoms are often overlooked, resulting in twice as many women waiting five or more years for a proper diagnosis compared to men. The conversation highlights the imperative to move beyond the "cookie-cutter" approach by leveraging new, objective diagnostic tools to aid early detection, prioritizing women's inclusion in clinical research, and adopting a compassionate, integrative model that places the patient at the center of their own wellness journey. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities. https://www.medscape.org/viewarticle/1002954

This episode features Dr. Jaideep Banerjee, Director of Global Clinical & Medical Affairs at Smith+Nephew, discussing the challenges of chronic wound care, the importance of standardized evidence-based practices, and insights from his recent large-scale study on enzymatic debridement. Dr. Banerjee shares strategies for improving patient outcomes, reducing costs, and building a strong foundation for long-term healing.This episode is sponsored by Smith+Nephew.Important Safety InformationIndication: Collagenase SANTYL Ointment (“SANTYL”) is indicated for debriding chronic dermal ulcers and severely burned areas. Contraindications: SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Warnings and Precautions: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for wound closure. Discontinue use of SANTYL after granulation tissue is well-established. Adverse Reactions: No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. To see the complete Prescribing Information, please see the FDA-approved product labeling, here: https://www.santyl.com/pdf/SANTYL-PI.pdf. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

In this episode of IDEA Collider, we are joined by Alex Telford, a biotech founder, writer, and thinker based in the San Francisco Bay Area. As the co-founder of Convoke Bio, Alex discusses his journey from studying biochemistry at UCL to founding a company that develops software tools for streamlining biopharmaceutical workflows.The conversation dives into the impact of AI and language models on the biotech industry, addressing inefficiencies in drug development, and exploring the potential of synthetic biology and personalized medicine. The discussion also touches on the future of drug discovery, China's role in biotech, and the challenges of understanding neuroscience and consciousness. Don't miss this insightful discussion on the future of biopharma innovation! 00:00 Welcome to Idea Collider00:04 Introducing Alex Telford01:59 Alex's Journey from UCL to Convoke Bio05:29 The Mission and Work of Convoke Bio07:57 Challenges in Pharma Decision Making14:05 The Role of AI in Pharma18:26 Knowledge Management and AI27:58 Staying Updated in the Fast-Moving AI Field30:25 AI's Impact on Industry Economics31:38 AI in Clinical Trials and Drug Development35:56 China's Role in Drug Discovery39:24 Neuroscience and AI: Blurring the Lines46:05 Future Predictions in Pharma51:20 Addressing Cognitive Bias in Pharma53:13 Concluding Thoughts and Future Directions Keep up with Alex Telford;LinkedIn: https://www.linkedin.com/in/alexander-telford/Website: atelfo.github.ioX: https://twitter.com/atelfoSubstack: atelfo.substack.com Follow Mike Rea On;Website: https://www.ideapharma.com/X: https://x.com/ideapharmaLinkedIn: https://www.linkedin.com/in/bigidea/ Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/

In this episode, Kevin Kelleher (Director of Medical Affairs at Medtronic & founder of the Rural Health Technology Consortium) shares his journey from nurse to sales leader, and why passion, and not just money, must drive your career.Kevin's story really stuck with me. He went from nursing into sales, but what makes his perspective different is how he ties everything back to passion and purpose. He also opens up about what it's like serving rural communities, the push for more diversity in clinical research, and even how he balances leadership with family life. Honestly, it's one of those conversations that leaves you rethinking your life. From breaking into medical sales, building trust in rural healthcare, and tackling diversity in clinical research, to leadership, productivity, and family balance... Kevin brings powerful lessons you can apply today.

Before she turned eight, Cerys had already faced two diagnoses, only one of which she truly understood. While being diagnosed with celiac disease as a child, unusually high CK levels in her blood pointed to a deeper issue: limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In this episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio Gene Therapy, speak with Cerys, a 23-year-old living in Wales, about living with LGMD2I/R9. She shares how she's navigated symptom progression, adapted to using mobility aids, and discovered the power of telling her story through her podcast, Unbalanced. When Cerys was first diagnosed with LGMD2I/R9 at age seven 7 years old, she didn't fully understand the diagnosis. Her parents carried the emotional weight, trying to protect her from fear of what was ahead. It wasn't until her muscle weakness became impossible to ignore, at 12 years old, that the condition began to define her daily life. From navigating stairs and driving to embracing a wheelchair, Cerys has had to adapt physically, emotionally, and socially, all while managing her energy levels so that she can continue to do the activities she loves. She finds strength in the LGMD community and hope in research, representation, and connection. In 2023, she launched Unbalanced to amplify stories like hers because growing up, she didn't see anyone with a disability who looked like her. Now, she's determined to be that voice for others. Dr. Anna Talaga, Director of Medical Affairs at ML Bio Solutions (a BridgeBio affiliate), provides a medical overview of LGMD. LGMDs are a group of genetic diseases that cause progressive muscle weakness and wasting, particularly in the shoulders, hips, and thighs. In some people, the heart and respiratory muscles may be impacted. Unlike many genetic conditions that are caused by a mutation in a single gene, LGMD can result from mutations in many different genes because they all affect the same protein complex that supports and stabilizes muscle fibers. LGMD type 2I/R9 (LGMD2I/R9), specifically, is caused by mutations in the FKRP gene, which is critical for maintaining muscle fiber integrity. Diagnosis typically begins with symptoms like difficulty walking, climbing stairs, or standing from a seated position, and is confirmed through genetic testing. LGMD2I/R9 is a progressive disease and there are currently no approved treatments that slow or stop its progression.

Abdul Hameed joins me on 5 in 5 to share how Medical Affairs acts as the bridge between science, patients, and commercial success. In just five minutes, we break down five actionable lessons you can use right now—from measuring real impact, to designing with patients, to applying AI responsibly.Quick, practical, and ready to implement. 

This three-part podcast explores how Medical Affairs leaders can navigate and lead through disruption with clarity, structure, and resilience.This episode defines crisis management as a structured, cyclical process: preparedness, response, recovery, and reflection. We discuss how Medical Affairs plays a unique role in translating uncertainty into strategy, maintaining scientific clarity, and protecting external trust through transparent communication.

The effort to deport is expanding, as Nebraska agrees to help with immigration enforcement, creating a new detention facility dubbed "the Cornhusker Clink." Restoring law and order at the border was a big campaign promise of President Trump, and now CBP data show border apprehensions have hit new lows. Nebraska Governor Jim Pillen joins the Rundown to discuss the Trump administration's efforts in reeling in illegal immigration. There's a presidential push to lower drug prices, which are not only higher than in other countries but can vary from one pharmacy to the next. President Trump sent letters to 17 different pharma companies asking them to commit to cutting drug prices by September 29th. CEO of the Accreditation Council for Medical Affairs, Dr. William Soliman, joins the podcast to talk about this price-cutting deadline and why Americans pay so much more for prescription drugs. Plus, commentary from FOX News Contributor Joe Concha. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

The effort to deport is expanding, as Nebraska agrees to help with immigration enforcement, creating a new detention facility dubbed "the Cornhusker Clink." Restoring law and order at the border was a big campaign promise of President Trump, and now CBP data show border apprehensions have hit new lows. Nebraska Governor Jim Pillen joins the Rundown to discuss the Trump administration's efforts in reeling in illegal immigration. There's a presidential push to lower drug prices, which are not only higher than in other countries but can vary from one pharmacy to the next. President Trump sent letters to 17 different pharma companies asking them to commit to cutting drug prices by September 29th. CEO of the Accreditation Council for Medical Affairs, Dr. William Soliman, joins the podcast to talk about this price-cutting deadline and why Americans pay so much more for prescription drugs. Plus, commentary from FOX News Contributor Joe Concha. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

The effort to deport is expanding, as Nebraska agrees to help with immigration enforcement, creating a new detention facility dubbed "the Cornhusker Clink." Restoring law and order at the border was a big campaign promise of President Trump, and now CBP data show border apprehensions have hit new lows. Nebraska Governor Jim Pillen joins the Rundown to discuss the Trump administration's efforts in reeling in illegal immigration. There's a presidential push to lower drug prices, which are not only higher than in other countries but can vary from one pharmacy to the next. President Trump sent letters to 17 different pharma companies asking them to commit to cutting drug prices by September 29th. CEO of the Accreditation Council for Medical Affairs, Dr. William Soliman, joins the podcast to talk about this price-cutting deadline and why Americans pay so much more for prescription drugs. Plus, commentary from FOX News Contributor Joe Concha. Photo Credit: AP Learn more about your ad choices. Visit podcastchoices.com/adchoices

What does “great” Medical Affairs look like in 2025? We talk evidence, access, patient voice, and how to work with Commercial without crossing the promotional line. Abdul Hameed Al-Khateeb, Country Medical Director, shares practical lessons on measurement, real-world evidence, and where AI actually helps.Email to your listSubject line options (pick one):Inside Medical Affairs: From Evidence to AccessThe Missing Link Between Science and PatientsWhat Great Medical Affairs Looks Like (and How to Measure It)

The Learning Objectives for this podcast are to understand the scope and requirements of the main privacy laws and regulations, covering data types and processing activities including collection, usage, data retention, subjects' rights and much more.This podcast also considers the risks and practical application of the regulations in the conduct of various Medical Affairs activities.

About this episode:  Sickle cell disease affects an estimated 100,000 people in the United States. Recent advancements in gene therapies and medicines like hydroxyurea are diminishing extreme pain, reducing strokes, and extending survival times for those afflicted by the disease. In this episode: leading sickle cell disease expert Dr. Mark Gladwin explains how revolutionary new treatments work and discusses the challenges to access to life-saving care. Guest: Dr. Mark Gladwin is a physician-scientist and the Dean of the University of Maryland School of Medicine and Vice President for Medical Affairs at the University of Maryland, Baltimore. His research focuses include sickle cell disease and hypertension. Host: Dr. Josh Sharfstein is vice dean for public health practice and community engagement at the Johns Hopkins Bloomberg School of Public Health, a faculty member in health policy, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle—CNBC Gene Therapy: What You Need to Know—Sickle Cell Disease Association of American No More Pain: Breakthrough Sickle Cell Treatment from Johns Hopkins Offers Curative Potential—Johns Hopkins School of Medicine Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator). Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing.⚡️ WHAT YOU'LL LEARN:- Why medical affairs and regulatory teams can't rely on ChatGPT alone.- How MACg integrates real‑time PubMed search, citation generation, and secured collaboration to streamline scientific writing - Why MACg users report up to 50 % faster writing and 50–70 % faster medical-legal review.- Why AI platforms like MACg must be purpose-built for life sciences (GDPR & SOC 2 compliant).- What is “human-in-the-loop” AI workflow—and how it balances automation and review to maintain accuracy and trust.- Real-world use cases: scientific summaries, medical info letters and more.

From chatbots and content generation to insights mining and decision support, GenAI is moving from buzzword to backbone. In this "Elevate" episode, our hosts Jennifer Riggins & Steve Casey speak to a panel of experts on the frontlines of GenAI implementation to share their hard-won insights.

In this episode of Transforming Medical Communications, Wesley Portegies is joined by MedComms strategist, J.R. Meloro, to discuss why mastering smarter metrics is no longer optional for Medical Affairs leaders; it's a necessity. Learn how to move beyond outdated metrics and implement smarter, more meaningful measurement strategies. Metrics should be your roadmap to better decisions, but only if you know how to use them effectively. The future of Medical Affairs depends on how well you track and act on data; those who don't evolve will fall behind.

It’s no secret that our lifespans – especially women’s – have drastically increased over the last several decades, but what about healthspans? How can we make those additional years healthier and happier? Speaking live at City Winery in NYC, join Katie and Dr. Krys Araujo-Torres, Head of U.S. Medical Affairs for Nature's Bounty, as they dig into the simple, effective steps we can take to live our best lives. #adSee omnystudio.com/listener for privacy information.

Welcome to Health-e Law, Sheppard Mullin's podcast exploring the fascinating health tech topics and trends of the day. In this episode, Sara Shanti welcomes Bill Kish and Dr. Brad Pruitt of Kenosha AI to explore how artificial intelligence can enhance efficiency and compliance in healthcare research. What is Kenosha AI, and what is its potential role in transforming healthcare and research operations? Who are the end users of Kenosha AI's products, and how are these products positioned to deliver immediate, tangible impacts for their missions? Looking ahead, how might this momentum build, and what direction could clinical research take with the advancements enabled by AI? What are the risks and concerns associated with hallucinations, synthetic data, and the trustworthiness of AI deliverables? Where can healthcare stakeholders feel comfortable jumping in on AI, and where does it make sense to wait for further development? What tasks should clinicians and researchers prioritize when exploring the potential applications of AI?   About Bill Kish Bill Kish is the CEO and Co-Founder of Kenosha AI, bringing over 30 years of dynamic experience as a technologist, entrepreneur, and leader across five successful startups. His expertise has led burgeoning companies to flourish into multi-billion-dollar enterprises, solidifying his position as an industry innovator. A graduate with honors in Computer Engineering from Carnegie Mellon University, Bill's career has been defined by groundbreaking advancements in AI and machine learning applications. He co-founded Ruckus Wireless, serving as CTO and Board Director, where his contributions shaped the company into a $400M/year business and a leader in the wireless technology industry, culminating in a $1.5 billion acquisition by Brocade. At Cogniac Corporation, Bill enabled industries to leverage AI-powered visual inspection, serving as the CEO and CTO to drive operational innovation. He also founded Jiggy AI, a boutique AI consulting firm specializing in large language model applications. Additionally, as the organizer of the Silicon Valley Machine Learning Meetup, Bill has fostered a thriving global community of over 10,000 members passionate about machine learning. About Dr. Brad Pruitt Dr. Brad Pruitt is the President and Co-Founder of Kenosha AI. With over 25 years of experience in clinical research and healthcare, including 13 years in the Contract Research Organization (CRO) industry, he specializes in revolutionizing clinical trials through advanced AI-powered tools like copilots and GPTs.  Dr. Pruitt is a seasoned executive and entrepreneur with a proven track record of leading ventures to success. He has held executive roles at top-tier CROs, served as the Founding CEO of an acquired startup, and contributed to three successful acquisitions in the past eight years. His prior leadership roles include Chief Medical Officer at Alethium Health Systems, where he developed go-to-market strategies for clinical trial innovation, and Senior Vice President of Medical Affairs at Safe Health, where he drove business expansion into connected diagnostics.  In addition to his role with Kenosha AI, Dr. Pruitt is a Principal at Prucor and serves as a mentor and advisor for healthcare and clinical trial technology companies participating in the EvoNexus incubator program. Dr. Pruitt earned his MD from Michigan State University College of Human Medicine and his MBA from UC San Diego's Rady School of Management. His academic foundation, combined with his professional achievements, positions him as a visionary leader at the intersection of technology, healthcare, and clinical research. About Sara Shanti A partner in the Corporate Practice Group in Sheppard Mullin's Chicago office and co-lead of its Digital Health Team, Sara Shanti's practice sits at the forefront of healthcare technology by providing practical counsel on novel innovation and complex data privacy matters. Using her medical research background and HHS experience, Sara advises providers, payors, start-ups, technology companies, and their investors and stakeholders on digital healthcare and regulatory compliance matters, including artificial intelligence (AI), augmented and virtual reality (AR/VR), gamification, implantable and wearable devices, and telehealth. At the cutting edge of advising on "data as an asset" programming, Sara's practice supports investment in innovation and access to care initiatives, including mergers and acquisitions involving crucial, high-stakes and sensitive data, medical and wellness devices, and web-based applications and care.   Contact Information Bill Kish Dr. Brad Pruitt Sara Shanti   Additional Resources Kenosha AI - Kenosha AI is currently offering a free trial of its RegChatTM, which is an AI-powered Clinical Regulatory Guidance Assistant that provides a simple chat interface for answering questions about global regulatory guidance using AI and official regulatory guidance documents with referenced summarizations and multi-agency comparisons. Find it at RegChat.com.  Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

Being a pharmacist is exciting–as long as you're willing to try new things. These are wise words from my returning guest on today's podcast, who has been paving the way for integrative pharmacy. Dr. Swathi Varanasi is an award-winning pharmacist passionate about the intersection of personalized medicine, patient outcomes, and innovation. With experience spanning patient care, biotech, research, academia, and consumer product goods, Dr. Swathi has paved the way for healthcare professionals to pursue non-traditional career paths through creating postdoctoral training programs, industry internships, and online educational programs. She co-founded and serves as Chief Scientific Officer of the Life Sciences Division at Element Apothec, and serves as a Principal Investigator at contract research organization, Citruslabs. Dr. Swathi received her Doctor of Pharmacy (PharmD) at the Medical University of South Carolina and Bachelor of Arts (BA) at Carleton College. She was the first-ever pharmacist in the United States with formal residency training to specialize in integrative medicine and preventative health. She also completed a postdoctoral fellowship in Medical Affairs in biotech and has training in nutrition from Cornell University. Dr. Swathi has served as faculty and guest lectures at colleges and universities across the country. She is an advisor and consultant for a number of for-profit and nonprofit organizations aiming to make the world a healthier place for us to live–and thrive. She has been published in peer-reviewed academic journals and featured in Yahoo, mindbodygreen, Well+Good, Entrepreneur, Forbes Health, and more. In 2023, Dr. Swathi was voted one of the 50 Most Influential Leaders in Pharmacy. Connect with Dr. Swathi via: Email: swathimvaranasi@gmail.com  FB: Doctor Swathi  IG: @drswathivaranasi Linked In:Dr. Swathi Varanasi  Check out our earlier episode here: https://www.marinabuksov.com/s03e03-paving-the-unconventional-path-with-integrative-pharmacist-dr-swathi-varanasi/ 

In this candid and wide-ranging conversation, we sit down with Dr. Brian Schmutzler — anesthesiologist, social media educator, and Executive Vice President of Medical Affairs at CCI Anesthesia — to unpack what it really means to lead in modern anesthesia. From the realities of staffing rural hospitals without anesthesiologists to fighting burnout, navigating private equity, and fiercely defending provider scope and safety, Brian shares hard-earned insights from both clinical and corporate perspectives.We also dive into the power of humor and education on social media, his 108K-strong Instagram following, and how his content brings awareness, advocacy, and levity to patients and practitioners alike.If you're a CRNA, MD, administrator, or just someone trying to understand where anesthesia is headed — and how to lead within it — this is an episode you can't miss.Keywords:Leadership, Anesthesia, Social Media, Burnout, Independent PracticeSend us a textFollow us at:InstagramFacebookTwitter/X

What is the environmental impact of respiratory illness? Find out in this episode of the EMJ GOLD podcast, where Shish Patel, Medical Director, Chiesi UK, joins Isabel to discuss the rising burden of COPD and the impact of respiratory care on the planet.  Together, the two explore the diagnostic gap in COPD, improving the experience of people living with the disease, balancing health innovation with climate concerns and much more.   A little more on EMJ GOLD's guest…  Shish Patel trained as a pharmacist and has worked in the pharmaceutical industry for over 30 years. Currently, he serves as Medical Director at Chiesi UK and Ireland, and he has held senior positions within medical and scientific functions at both affiliate and global level throughout his career. In addition to his significant time at Chiesi, Shish has held positions at GSK and Sanofi. Shish also holds key industry board positions including at the Prescription Medicines Code of Practice Authority and the ABPI.   

In this solo episode of Transforming Medical Communications, host Wesley Portegies draws from the 2025 State of MedComms survey to explore what pharma teams truly want from their agency partners. And the answer isn't more slide decks. It's strategy. Wesley breaks down the five capabilities that Medical Affairs leaders expect from modern agencies, ranging from scientific depth to digital fluency, and explains why empathy, insight, and operational awareness are just as important as technical skill. He also shares a practical example that reveals the difference between a transactional vendor and a true thought partner, and offers clear steps to activate more strategic collaboration.

This episode recorded live at the Becker's 3rd Annual Spring Payer Issues Roundtable features Illan Shapiro Strygler, Chief Health Correspondent and Medical Affairs Officer and Senior Vice President, AltaMed Health Services. Dr. Shapiro shares how AltaMed leverages data, cultural understanding, and community connection to improve care quality, reduce costs, and advance health equity.

This episode recorded live at the Becker's 3rd Annual Spring Payer Issues Roundtable features Illan Shapiro Strygler, Chief Health Correspondent and Medical Affairs Officer and Senior Vice President, AltaMed Health Services. Dr. Shapiro shares how AltaMed leverages data, cultural understanding, and community connection to improve care quality, reduce costs, and advance health equity.

In this special edition of the EMJ GOLD podcast, Isabel and Jade dive into the latest insights from recent contributors and EMJ's own data to uncover what healthcare professionals really want from medical affairs. They explore the growing challenges of engaging HCPs, question whether there's a gap between what HCPs say they want and what actually captures their attention and look ahead to what the future may hold. Tune in for expert insights from guests including Dr Donatello Crocetta, Bora Erdemli, Cécile Janssenswillen, Dr Natalia Barkalina and Dheepa Chari.

During this episode you'll learn about: This week's guest: Dr. Mario Roxas, ND, Director of Scientific and Medical Affairs at Thorne [0:57] Travel's effects on the body, from jet lag to immune challenges [2:10] Roxas' top 3 supplements for travel [3:51] Common health challenges from travel [6:21] How to prepare for digestive upset [10:08] Tips for combating jet lag and staying rested while traveling [12:26] Questions from the community How do you choose which foods to try and which to avoid while traveling? [17:19] What causes traveler's constipation? [20:09] Can I pass through airport security and TSA checkpoints with powder supplements? [21:06] Resources to topics mentioned in this episode: What Inspires Us to Innovate, with Mario Roxas, Director of Research and Development Tips for Healthy Traveling This Summer Mayo Clinic: The Globetrotter's Guide to Dealing with Gut Health Issues While Traveling These Are the Ideal Supplements to Pack While Traveling Mayo Clinic: A Traveler's Guide to Immunity Health Keep Your Gut Healthy While Traveling Mayo Clinic: Don't Let Jet Lag Derail Your Vacation Can You Bring Vitamins on a Plane? How To Travel with Supplements How Does Thorne Support Traveling Athletes? Products related to this episode: Daily Greens Plus, Sacro-B™, Daily Electrolytes, Advanced Digestive Enzymes, Magnesium Bisglycinate, Melaton-3™ Subscribe to More Content Subscribe to the show wherever you listen to podcasts so you never miss an episode. You can also learn more about the topics in the episode by checking out the latest news, videos, and stories on Thorne's Take 5 Daily blog.

Getting an autoimmune disease diagnosis can feel like solving a medical mystery. In this powerful interview, we explore why so many people struggle for years before finally receiving answers. From vague symptoms and misdiagnoses to medical gaslighting and gaps in conventional testing, we break down the challenges of getting properly diagnosed—and what you can do to advocate for yourself along the way. If you've ever felt dismissed or overlooked by the healthcare system, this episode is for you. I talk with a medical expert on the science of autoimmune disease diagnosis about why doctors can have such a hard time with autoimmune disease diagnoses.  Tyler O'Malley serves as Associate VP of Clinical Affairs & Market Access at Exagen Inc., a leader in autoimmune testing solutions. In his role, he oversees clinical trials, bioinformatics, and medical policy development for Exagen's current diagnostic portfolio and pipeline of proprietary solutions. With more than a decade of experience, O'Malley has contributed to more than a dozen clinical trials, focusing on clinical validity and utility evidence for autoimmune diagnostics. His expertise is widely recognized, with numerous publications in esteemed peer-reviewed journals. Notably, he is the first author of one of the largest clinical utility studies in lupus diagnostics. O'Malley graduated from Georgia Gwinnett College with a Bachelor of Science in biology, concentrating in biochemistry. His eleven-year career in Research and Development and Medical Affairs encompassed medical science education, assay development, and clinical research coordination. http://exagen.com Website for this episode: http://autoimmunerehab.com Youtube channel: https://youtube.com/c/annalaurabrownhealthcoach  

In this episode, Kristen is joined by Dr. Marschall Runge, Executive VP for Medical Affairs at the University of Michigan and author, to explore how true healthcare disruption begins with integrating emotional and mental health into patient care. They discuss the promise and limitations of AI in medicine and why supporting the mental well-being of healthcare providers is more essential than ever.     https://drmarschallrunge.com/ https://www.codedtokill.com/     When you purchase these books through these Amazon links, you're helping support the podcast at no extra cost to you. 1. The Great Healthcare Disruption (Audiobook): Big Tech, Bold Policy, and the Future of American Medicine: https://amzn.to/3FHmjsi 2. The Great Healthcare Disruption: Big Tech, Bold Policy, and the Future of American Medicine Hardcover: https://amzn.to/45gZyFV Recommendations: 1. Super Agers: An Evidence-Based Approach to Longevity: https://amzn.to/4mYbwe8 2. Make Magic: The Book of Inspiration You Didn't Know You Needed: https://amzn.to/4l17CiM     Subscribe and get a free 5-day journal at www.kristendboice.com to begin closing the chapter on what doesn't serve you and open the door to the real you. This information is being provided to you for educational and informational purposes only. It is being provided to you to educate you about ideas on stress management and as a self-help tool for your own use. It is not psychotherapy/counseling in any form. This information is to be used at your own risk based on your own judgment.  For my full Disclaimer please go to www.kristendboice.com. For counseling services near Indianapolis, IN, visit www.pathwaystohealingcounseling.com. Pathways to Healing Counseling's vision is to provide warm, caring, compassionate and life-changing counseling services and educational programs to individuals, couples and families in order to create learning, healing and growth.

In this episode, Dr. Terrance Govender, VP of Medical Affairs at ClinIntell, discusses solving the physician engagement puzzle & why it matters for hospital finance.

In this episode of Medical Affairs unscripted, Peg Crowley-Nowick, PhD, MBA, Senior Advisor, Medical Affairs Consulting at Lumanity, and Cathy Symonds, PhD, Program Lead and Head of New Product Planning at Arbor Biotechnologies, engage in an insightful discussion about the evolving role of new product planning and its intersection with Medical Affairs. Peg and Cathy explore the strategic importance of new product planning in the lifecycle of medical products, emphasizing how early commercial strategy is essential for successful development and market entry. They discuss various frameworks and best practices, including the creation of a Target Product Profile (TPP), which helps align the team on what success looks like and guides the development process from early stages through to commercialization. The conversation delves into the critical partnerships between new product planning and other functions such as Medical Affairs, clinical development, and market access. They highlight how these collaborations are essential for gathering comprehensive insights from healthcare professionals, patients, and the broader market landscape. They share their experiences and perspectives on the importance of strategic narratives that communicate the value of new products effectively to both internal teams and external stakeholders, including investors. Throughout the discussion, they underscore the necessity of continuous planning and adaptation to ensure that products not only meet regulatory requirements but also achieve commercial success and ultimately improve patient outcomes.

Today's guest is Dr. Ankur Sharma, Head of Medical Affairs for Medical Devices and Digital Radiology at Bayer. Dr. Sharma joins Emerj Editorial Director Matthew DeMello to explore the complex intersection of AI, medical devices, and data governance in healthcare. Dr. Sharma outlines the key challenges that healthcare institutions face in adopting AI tools, including data privacy, system interoperability, and regulatory uncertainty. He also clarifies the distinction between regulated predictive models and unregulated generative tools, as well as how each fits into current clinical workflows. The conversation explores the evolving roles of the FDA and EU AI Act, the potential for AI to bridge clinical research and patient care, and the need for new reimbursement models to support digital innovation. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

MedComms is overdue for a reboot. Static PDFs. Oversized decks. Siloed teams. No feedback loops. These outdated practices are slowing teams down and wasting valuable resources. In this episode of Transforming Medical Communications, Wesley Portegies shares bold insights from the State of Medical Communications 2025 survey and breaks down three urgent trends that pharma leaders can't afford to ignore. From dismantling silos to killing the static PDF once and for all, this episode offers a practical roadmap to modernize how Medical Affairs teams create, deliver, and measure content.

Dr. William Soliman is the founder and CEO of the Accreditation Council for Medical Affairs (ACMA). The ACMA is America's leader in life sciences accreditation, certification & training.  Soliman is a former pharmaceutical executive who worked in leadership roles at Merck, Abbvie, Gilead and more. He is considered a pharma industry futurist and has been featured on NewsNation, Fox News, Newsmax, Forbes, Al Jazeera, Yahoo Business TV, ABC News Radio & more. The ACMA established the first ever certification standards in the United States and stands as a benchmark of excellence for prior authorization professionals, reimbursement professionals, pharmaceutical sales professionals, medical science liaisons and medical affairs professionals.  Dr. Soliman received his PhD from Columbia University & his BA from New York University.

Marschall S. Runge, M.D., Ph.D., is the executive vice president for Medical Affairs at the University of Michigan, dean of the Medical School, and CEO of Michigan Medicine. He earned his doctorate in molecular biology at Vanderbilt University and his medical degree from Johns Hopkins School of Medicine, where he also completed a residency in internal medicine. He is the author of more than 250 publications and holds five patents for novel approaches to healthcare.  Today we talk about his new novel, “Coded to Kill: A Techno Medical Thriller.”  It is a supercharged fictional story about  how advancing technology in medicine is exploited with by a power hungry cabal and the offbeat cybersecurity team out to stop them.  A tough book to put down!

In this eye-opening conversation, we sit down with Dr. Ingrid Skop — a board-certified OB/GYN and Vice President of Medical Affairs at the Charlotte Lozier Institute — to unpack the critical issues surrounding women's health care. Dr. Skop shares her firsthand medical insight on the realities of abortion procedures, the risks of substandard care, and what women really need when facing unplanned pregnancies.We explore alternatives to abortion clinics, the importance of parental involvement laws, and the decline of essential services like cancer screenings and contraception. With compassion and clarity, Dr. Skop sheds light on what true, comprehensive care looks like — and how we can better support women both physically and emotionally.This is a conversation about facts, not politics. About healing, not headlines. And most of all, about the value of every woman and every life.https://lozierinstitute.org/team-member/ingrid-skop-m-d-facog/Recent News Summary:Leading up to a major budget vote in Congress, the U.S. House Rules Committee held an intense 21-hour hearing packed with high-profile Democratic leaders — including Minority Leader Hakeem Jeffries, House Whip Katherine Clark, and former Speaker Nancy Pelosi — pushing for amendments that included increased welfare spending without work requirements and continued funding for Planned Parenthood.One of the central points of contention was the claim that proposed budget cuts represented the “largest cut to health care in American history.” Critics argue that equating abortion with healthcare is misleading and point to serious concerns about Planned Parenthood's practices.Reports — including a disturbing exposé from The New York Times — have shed light on troubling conditions in some Planned Parenthood facilities, including botched procedures, leaking sewage, and poor medical oversight. These revelations come amid ongoing scrutiny of the organization's influence and funding, with statistics showing:    Nearly 400,000 abortions annually performed by Planned Parenthood — about 40% of all abortions in the U.S.    A 97% abortion rate for pregnant women who visit their clinics.    A decline in other services: cancer screenings, pap smears, and contraception services have all dropped sharply.    $2 million per day in taxpayer funding still flows to the organization, despite these declines.    Meanwhile, over 5 women have reportedly died from complications related to abortions performed there.Critics also highlight that there are over 15 times more community health centers nationwide that provide broader, life-affirming care without performing abortions — offering a more comprehensive and safer option for women in need.House Speaker Mike Johnson vowed to push the bill through by July 4th, saying the time has come to redirect federal resources toward truly compassionate and high-quality women's healthcare.Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.

In this episode, you'll hear a conversation with three women's health experts about how early diagnostic testing is transforming care for heart disease, STIs, and preeclampsia. Discover how proactive screening empowers women, supports personalized care, and helps shift healthcare from reaction to prevention.   About Our Speakers:  Dr. Lindy Crimmins, Global Medical Affairs Manager. Lindy's clinical experience spans from emergency medicine to critical and primary care. Currently, she is responsible for providing medical support for the QuidelOrtho acute care menu throughout the product lifecycle. Lindy is passionate about education, testing guideline updates and assay utilization to drive improved patient-centered outcomes. Dr. Rea Castro, Director of Medical Affairs. Rea is a seasoned medical professional with extensive experience in pharmaceutical clinical development, biotechnology and diagnostic product development across multiple therapeutic areas, including immunology, oncology and women's health. She is currently a cross-functional leader in medical affairs and is committed to advancing healthcare outcomes through innovative research, quality healthcare delivery and rigorous safety standards. Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Marschall Runge, Dean, University of Michigan Medical School; Executive Vice President, Medical Affairs, University of Michigan; and CEO of Michigan Medicine. Dr. Runge shares insights on leading a complex academic health system, driving integration across hospitals, managing financial headwinds, and embracing AI and digital innovation to shape the future of care.

Marc Cox talks with Dr. William Soliman, Founder and CEO of the Accreditation Council for Medical Affairs, about the administration's historic push to lower drug prices—particularly for Medicare patients. Dr. Soliman breaks down why Americans pay up to 15 times more for medications than those in other countries, the role of pharmacy benefit managers in inflating costs, and how pharmaceutical companies navigate R&D timelines and profit windows. They also explore the market dynamics behind global drug pricing and challenges facing privately insured patients in accessing life-saving medications.

Hosted by Drew Beck, Head of Strategy, Growth and Innovation for Syneos Health Learning Solutions, this limited series dives into the breakthrough trends redefining health in 2025 and beyond. From bold moves in R&D and medical affairs to next-gen trial design, product launch strategies and the future of healthcare communications, each episode connects you with the minds driving real change. Big ideas. Real-world impact. In this episode, Drew dives into launch excellence in 2025 with Syneos Health experts Larry Dollar, VP of Medical Affairs, and Michael Sarshad, Managing Director, Consulting. Together, they unpack how strategic spending, agile planning and early investment in medical resources are driving launch success. They explore the rise of new medical affairs roles using the transformative impact of AI on clinical trials, and the evolving needs of field teams. The discussion also highlights how innovations like machine learning–driven physician segmentation are helping companies identify new clinical trial sites faster and more precisely. Whether you're with an emerging biotech or a large pharma company, you'll get key insights on collaboration, creativity and why the year leading up to launch is more critical than ever. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Sometimes the signs of heart trouble in women don't look like what we expect—they show up as hot flashes, brain fog, or even a racing heart. When I sat down with Dr. Jayne Morgan, an incredible Cardiologist and Women's Health Advocate, we talked about how these often-overlooked symptoms during menopause can actually be clues about what's going on with your heart. We're so used to brushing things off as “just hormones,” but Dr. Jayne explains why now is the time to tune in and take them seriously. Dr. Jayne —who's not only a top Cardiologist but also Vice President of Medical Affairs at Hello Heart—is passionate about making sure women get the full picture when it comes to heart health. She breaks down how estrogen protects your heart, what happens when those levels drop, and why menopause can be a turning point for understanding your risk. We also talked about what real, thorough heart testing should include (because yes, there's more to it than just cholesterol). Her approach is practical, empowering, and honestly—something every woman deserves to hear. Women need to feel empowered, not dismissed, when they bring up symptoms—and that starts with education. We're talking about prevention, clarity, and how to stop second-guessing what your body's trying to tell you. And in line with this we'd like to empower our women, mothers especially, we'll be having a  Mother's Day Sale from May 7-11 ‘25 where we'll get you up to 25% off with bundles of your favorite products. Check out https://dranna.com for more information.   Key Timestamps: [00:00:00] Introduction. [00:05:38] Estrogen's role in heart disease. [00:10:53] What entails an adequate cardiac workup? [00:12:28] Prevention of heart disease. [00:15:47] Aggressive management of risk factors. [00:19:25] Statin therapy, hormonal management, lowering cholesterol. [00:23:57] Pregnancy as a stress test. [00:29:00] The connection of diabetes and cardiovascular disease risk. [00:30:57] The relation of heart disease to early dementia and early stroke. [00:32:22] Who can have hormone replacement therapy?   Memorable Quotes: "All of these symptoms in perimenopause and menopause are actually biomarkers for heart disease, biomarkers for stroke." [00:06:47] – Dr. Jayne Morgan "Heart disease is the number one killer of women, and you, as a patient or a member of the public, do not have the ability to discern whether your palpitations that you're having at home are related to your perimenopause or related to a real heart issue that could pose an impending heart attack." [00:09:08] – Dr. Jayne Morgan   Links Mentioned: Mother's Day Sale from May 7- 11 ‘25 – https://dranna.com   Connect with Dr. Jayne Morgan: Linktree: https://linktr.ee/DrJayneMorgan Instagram: https://www.instagram.com/drjaynemorgan/ YouTube: https://www.youtube.com/@DrJayneMorgan LinkedIn: https://www.linkedin.com/in/jaynemorgan/   Connect with Dr. Anna Cabeca: Website: https://drannacabeca.com/pages/show Instagram: https://www.instagram.com/thegirlfrienddoctor/ YouTube: https://www.youtube.com/@thegirlfrienddoctor TikTok: https://www.tiktok.com/@drannacabeca   Produced by Evolved Podcasting: https://www.evolvedpodcasting.com

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Dr. Isabelle Raymond is an author and scientific leader in pharmaceutical and biotech industries, more recently working in beauty and wellness. She has authored over 80 publications and textbook chapters and books in several therapeutic fields including aesthetic medicine, dermatology, sleep disorders and pain management. She is currently the Head of Clinical and Medical Affairs at Nutrafol. She joins the show to discuss the hair growth cycle, how our hair changes throughout different stages of life, and why clinical research is essential when it comes to nutraceuticals.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct, or indirect financial interest in products, or services referred to in this episode.Visit Nutrafol.com and enter code BLONDE for $10 off your first month and free shipping. Visit masachips.com and use promo code BLONDE to get 20% off your first order.Visit justthrivehealth.com and save 20% with promo code WellVisit oneskin.co/well and use code WELL for 15% off your first order.Produced by Dear MediaSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Skin Anarchy, we dive into the science of hair health with Dr. Isabelle Raymond, Senior VP of Clinical and Medical Affairs at Nutrafol. With a PhD in biomedical science and expertise in dermatology and pharmaceutical research, Dr. Raymond breaks down the science-backed approach Nutrafol takes to hair growth, scalp health, and supplementation.For years, the supplement industry has lacked regulation, leaving many consumers skeptical. Dr. Raymond shares how Nutrafol is changing the game with rigorous clinical trials, using macro photography, hair count analysis, and physician evaluations to ensure real, measurable results. Unlike products that focus solely on biotin, Nutrafol's formulas target stress, hormonal imbalances, gut health, and oxidative stress, recognizing that hair wellness starts from within.Women's hair health is often overlooked, especially when it comes to postpartum recovery and menopause. Dr. Raymond shares how Nutrafol's tailored formulations provide support through hormonal shifts and why addressing inflammation and nutrient absorption is key to maintaining strong, healthy hair at any age.Looking ahead, Nutrafol is at the forefront of new research into autoimmune-related hair loss, gut health, and inflammation, proving that supplements can be both safe and effective when backed by science.If you're curious about how to improve hair growth and scalp health with clinically proven solutions, tune in to this insightful episode of Skin Anarchy!To learn more about Nutrafol, visit their website and social media. Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform. Reach out to us through email with any questions.Shop all our episodes and products mentioned through our ShopMy Shelf!*Sponsored by Nutrafol Hosted on Acast. See acast.com/privacy for more information.